Background Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonine-to …

Background Resistance to tyrosine kinase inhibitors in patients with chronic myeloid
leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph …

Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-
ABL1T315I. The pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial …

Oral ponatinib (Iclusig®) is a novel kinase inhibitor structurally designed with a carbon-
carbon triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …

In 2012, ponatinib (Iclusig®), an orally available pan-BCR-ABL tyrosine kinase inhibitor
(TKI) developed by ARIAD Pharmaceuticals, Inc., was approved by the US Food and Drug …

Abstract Abstract 210 Background: Despite progress in CML therapy, patients (pts) who fail 2
or more tyrosine kinase inhibitors (TKI), or pts with T315I mutation, have no available …

BACKGROUND Effective treatment options for patients with chronic myeloid leukemia (CML)
or Philadelphia‐positive (Ph+) acute lymphoblastic leukemia (ALL) who have the threonine …

Ponatinib is approved for adults with refractory chronic myeloid leukemia or Philadelphia
chromosome–positive acute lymphoblastic leukemia, including those with the T315I BCR …

BCR-ABL1 kinase domain mutations can confer resistance to first-and second-generation
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). In preclinical studies …

Beginning with imatinib a decade ago, therapy based on targeted inhibition of the BCR-ABL
kinase has greatly improved the prognosis for chronic myeloid leukemia (CML) patients. The …